Walter Bushnell Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 16 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 25.66%
(FY 2023)
- Profit 32.70%
(FY 2023)
- Ebitda 35.97%
(FY 2023)
- Net Worth 23.01%
(FY 2023)
- Total Assets 16.60%
(FY 2023)
About Walter Bushnell Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Surendra Jangir, Prakash Sabherwal, and Padmakar Sawant serve as directors at the Company.
- CIN/LLPIN
U24232HR2008PTC071117
- Company No.
071117
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Mar 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Walter Bushnell Drugs Private Limited offer?
Walter Bushnell Drugs Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Infective Drugs & Medicines, Antiviral Drugs, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Common Disease Medicines, Pharmaceutical Tablets, Immunomodulator Drugs, Cardiovascular Drugs & Medication.
Who are the key members and board of directors at Walter Bushnell Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surendra Jangir  | Director | 25-Mar-2008 | Current |
| Prakash Sabherwal | Director | 25-Mar-2008 | Current |
| Padmakar Sawant | Director | 29-May-2019 | Current |
Financial Performance and Corporate Structure Insights of Walter Bushnell Drugs.
Walter Bushnell Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 25.66% increase. The company also saw a substantial improvement in profitability, with a 32.7% increase in profit. The company's net worth Soared by an impressive increase of 23.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Walter Bushnell Drugs?
In 2023, Walter Bushnell Drugs had a promoter holding of 79.61% and a public holding of 20.39%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Walter Bushnell Medicines Private LimitedActive 17 years 5 monthsSurendra Jangir is a mutual person
Walter Bushnell Medisafe Private LimitedActive 16 years 8 monthsPrakash Sabherwal is a mutual person
Walter Bushnell Pharmaceuticals Private LimitedActive 20 years 10 daysSurendra Jangir is a mutual person
Walter Bushnell Healthsciences Private LimitedActive 17 years 5 monthsPrakash Sabherwal is a mutual person
Walter Bushnell Biosciences Private LimitedActive 17 years 5 monthsPrakash Sabherwal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Walter Bushnell Drugs?
Walter Bushnell Drugs has a workforce of 143 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Walter Bushnell Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Walter Bushnell Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
